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Abstract 
Purpose. Epidemiological studies report strong positive associations between dietary silicon 
(Si) intake and bone mineral density (BMD) in pre-menopausal women and indicate that the 
association may be mediated by estradiol. We have tested this possibility in a mixed gender 
rodent intervention study. 
Methods. Tissue samples were obtained from three groups of 20-week old Sprague Dawley 
rats (five males and five females per group) that had been supplemented ad libitum for 90 
days in their drinking water with (i) < 0.1 mg Si/L (vehicle control) (ii) 115 mg Si/L 
(moderate dose) or (iii) 575 mg Si/L (high dose). All rats received conventional laboratory 
feed, whilst supplemental Si was in the form of monomethylsilanetriol, increasing dietary Si 
intakes by 18 and 99%, for the moderate and high dose groups, respectively.  
Results. Fasting serum and tissue Si concentrations were increased with Si supplementation (p 
< 0.05), regardless of gender. However, only for female rats was there (i) a trend for a dose 
responsive increase in serum osteocalcin concentration with Si intervention and (ii) strong 
significant associations between serum Si concentrations and measures of bone quality (p < 
0.01). Correlations were weaker or insignificant for tibia Si levels and absent for other serum 
or tibia elemental concentrations and bone quality measure.  
Conclusions. Our findings support the epidemiological observations that dietary Si positively 
impacts BMD in younger females, and this may be due to a Si-estradiol interaction. 
Moreover, these data suggest that the Si effect is mediated systemically, rather than through 
its incorporation into bone. 
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3 
Mini abstract 
Observational (epidemiological) studies suggest the positive association between dietary 
silicon intake and bone mineral density may be mediated by circulating estradiol level. Here 
we report the results of a silicon supplementation study in rats that strongly support these 
observations and suggest an interaction between silicon and estradiol.  
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Introduction 
Silicon, a major component of the mammalian diet via the consumption of plant-based foods, 
is present in all mammalian tissues and especially the connective tissues [1,2]. However, it is 
not clear whether it has a biological/biochemical role in higher animals, including mammals. 
Evidence amassed over the past 40 years suggests that Si may be important for normal bone 
and connective tissue health [1]. We have previously reported, in the Framingham Offspring 
cohort, that higher intakes of dietary Si are associated with higher BMD at the hip sites in pre-
menopausal women and to some extent in men but not at all in post-menopausal women [3]. 
These findings suggested that there may be an interaction between Si intake and estrogen 
status and this was investigated further in a female-only cohort (the Aberdeen Prospective 
Osteoporosis Screening Study) where post-menopausal use of hormone replacement therapy 
(HRT) was documented in detail. We confirmed the Si-BMD relationship in pre-menopausal 
women and the lack of association in post-menopausal women who had never taken HRT [4]. 
However, for post-menopausal women, the Si-BMD relationship was regained in past users of 
HRT and especially so in current users of HRT [4]. These findings, from observation studies, 
imply a possible interaction between Si intake and estrogen status.  
Others have also suggested a possible interaction between silicon and estrogen. Charnot 
& Peres [5,6] reported that endogenous sex and endocrine hormones affect the absorption and 
metabolism of Si in rats, while Nielsen & Poellot [7] reported that dietary Si (or Si status) 
affects the response to a change in estrogen status (i.e. ovariectomy/estrogen deficiency). Here 
we have taken advantage of rat tissue samples that were collected from a 12 week (90 day) 
oral intervention study with the Si supplement ‘monomethylsilanetriol’ (MMST, 
CH3Si(OH)3) to directly investigate the interaction between Si intake and oestrogen status 
with respect to bone health. The effect of Si supplementation on body Si pools (Si status) was 
investigated by measuring fasting Si levels in serum, ear (non-calcified collagenous tissue and 
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potential Si pool) and bone (calcified collagenous tissue and Si pool). The study was carried 
out by a commercial clinical research organisation for separate, regulatory purposes (i.e. a 
safety study), but it provided an opportunity for us to investigate the effects of three months 
Si supplementation on bone quality (bone microarchitecture and bone mineralisation) in male 
and female rats, where there is natural separation of circulating estradiol levels [8,9]. Silicon 
supplementation was given on a normal dietary Si background; i.e. this was not a deficiency 
study, the rats received a maintenance diet with its normal high Si content. 
Previous human studies have shown, over a one month intervention period, that MMST 
(CH3Si(OH)3) is a safe Si supplement and that it undergoes metabolism to orthosilicic acid 
(OSA, Si(OH)4) which is considered the bioactive form of Si [10,11]. Unlike OSA, however, 
this MMST precursor form has the advantage of remaining soluble and bioavailable at the 
supplemental levels used in this study [10-13].  
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Methods 
Animal study and tissue collection 
Rat tissue samples were collected at the end of a 90-day supplementation study with MMST, 
which was performed at a Good Laboratory Practice-accredited commercial clinical research 
organisation (CRO; Charles River Laboratories Pre-Clinical Services, Ireland). The study 
consisted of three groups each of ten rats: Group 1 = vehicle control (reverse osmosis treated 
drinking water with < 0.1 mg Si/L), Group 2 = 115 mg Si/L drinking water (‘moderate Si 
dose’) and Group 3 = 575 mg Si/L drinking water (‘high Si dose’). The drinking waters were 
prepared and provided by LLR-G5 Ltd (Castlebar, Ireland), with Si supplemented in the form 
of MMST (CH3Si(OH)3), and Si contents were confirmed in our laboratory. The supplemental 
dosing undertaken in this study was, primarily, for regulatory safety assessment purposes and, 
therefore, the doses were high. Each group consisted of five male (8 weeks old at start) and 
five female (8 weeks old at start and nulliparous and non-pregnant) Sprague Dawley rats 
(Charles River Laboratories, Margate, UK). All rats were individually housed in 
polypropylene cages with stainless steel lids (with dust-free sawdust as bedding) at 22 °C with 
a 12 h/12 h light/dark cycle. The drinking water, with and without the Si supplementation, 
was provided ad libitum in individual (dedicated) plastic drinking units. All rats also received 
ad libitum the same maintenance feed (2018 Teklad 18% Protein Rodent diet).  
Body weight and the consumption of the drinking waters were monitored on a daily 
basis, but feed intakes were not monitored. On day 89, the animals were fasted except for de-
ionised water with no added Si. Fifteen to sixteen hours later, on day 90, animals were 
anesthetised, terminal blood samples were collected, animals euthanised and necropsy 
performed. Fasting blood, sera, plasma and tissue samples were generated for clinical 
biochemistry analysis, haematological analysis, and histopathology at the CRO and were not 
avalable to the authors for the below analyses. In addition, sera (obtained without use of anti-
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coagulants), ears and tibias were also collected and stored at -80°C prior to being couriered 
frozen on dry ice to the authors’ laboratory for analysis. This study was approved by the 
animal Ethics committee of the CRO. 
 
Analyses 
A brief summary of the analyses is given below with more details in Online Supporting 
Materials. All samples were analysed in a blinded fashion. 
 
Serum 17β-estradiol 
Fasting serum samples were analysed for 17β-estradiol using a commercially available high 
sensitivity ELISA kit (Enzo Life Sciences UK Ltd, Exeter, UK) to confirm the higher 
circulating serum levels in female rats compared to male rats and to investigate potential 
changes in circulating levels with Si treatment.  
 
Serum osteocalcin 
Aliquots of fasting serum samples were also analysed for osteocalcin, a marker of bone 
formation/bone turnover, using the commercially available Rat N-Mid Osteocalcin kit 
(MyBioSource Inc, Sand Diego, USA). 
 
Total elemental analysis 
Total elemental analyses of the rodent feed, fasting serum samples and, one of the pairs of ear 
and tibia samples were carried out by inductively coupled plasma optical emission 
spectrometry (ICP-OES), Jobin Yvon 2000-2 (Instrument SA, Longjumeau, France), using 
peak profiles [12,14] and sample-based standards for Si and other elements. Serum iron and 
phosphorus were not measured, the latter due to possible haemolysis [15].  
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Bone quality measurements 
The second of the pair of tibias collected from each animal at necropsy was cleaned as 
previously described [16] at the authors’ laboratory and couriered, frozen on dry ice, from the 
authors’ laboratory to the Laboratory of Pathophysiology, University of Antwerp, Belgium 
for micro-CT analysis (Skyscan 1076 in-vivo X-ray micro-CT scanner, Aartselaar, Belgium). 
The following bone quality parameters (measures) were obtained: trabecular BMD (tBMD), 
tissue volume (TV), bone volume (BV), bone volume fraction (BV/TV), total surface (TS), 
bone surface (BS), bone surface/volume ratio (BS/BV), bone surface density (BS/TV), 
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N) and 
total porosity (Po(T)). 
 
Biomechanical testing 
Following bone quality measures, the tibias were subjected to three-point bending test at room 
temperature in a custom made loading device, integrated in a materials testing machine (Bose 
ElectroForce Test Bench LM1, Bose Corp, USA). The following parameters were obtained 
from the data collected: stiffness (k; N/mm), yield strength (Fy; N) and fracture load (Fmax; N). 
 
X-ray diffraction 
One tibia from each of the three groups of the female rats that had undergone micro-CT 
analysis underwent powder XRD analysis at the Institute for Materials Research, University 
of Leeds (UK) to determine changes in the mineral phase with Si supplementation. Prior to 
analysis the bones were processed [17] to remove organic components from the bone matrix 
that could interfere with the XRD analysis. 
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Statistical analyses 
Results are reported as means ± SD unless otherwise stated. Grubbs’ test for outliers was 
carried out (in GraphPad Prism 6; GraphPad Software Inc, La Jolla, US) on all the datasets 
collected. One of the serum Si values (1,120 µg/L), in a female rat from the ‘high’ Si dose 
group, was identified as a significant outlier (at p < 0.05) and is omitted from the data shown. 
Test for linearity was used to test for a dose-responsive increase in bone, serum and ear Si 
concentrations and serum osteocalcin concentration with Si supplementation and significance 
was taken as p ≤ 0.05. In the absence of a significant trend, individual group differences 
between Si treatments and diluent control were then assessed by independent (unpaired) 
Samples 2-Tailed T-test and because there was comparison for two groups (moderate and 
high Si dosing) a Bonferroni correction was applied to the p value (i.e. p/n), and significance 
was taken as p ≤ 0.025. Pearson correlation (with 2-Tailed T-test) was used to test for 
correlations between fasting serum and tibia element concentrations with bone quality 
measures. All statistical analysis was conducted in IBM SPSS version 21 (IBM Corporation).  
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Results 
Serum 17β-estradiol concentrations 
Fasting serum levels of 17β-estradiol, in the samples collected at necropsy, were, on average, 
1.7-fold higher in female rats compared to male rats (94.8 ± 20.6 vs 57.9 ± 12.6 pg/ml; p = 
0.0002; Supplementary Figure 1). 
 
Silicon intakes and body weights 
The feed (chow pellets) consumed by all groups contained, on average, 610 µg Si/g feed 
(Supplementary Table 1) and, assuming typical average feed intakes of 23 g feed/day in adult 
female rats and 32 g feed/day in adult males rats of the same strain [18], this would contribute 
~ 14 and 19 mg Si to daily Si intakes, respectively. Mean daily intake of Si from drinking 
waters (supplemented with and without Si) are shown in Table 1, separately for male and 
female rats, and did not differ between genders: overall mean Si intakes from the moderate 
and high Si-supplemented drinking waters added a further 18 and 99% Si to that from the 
feed. 
Weight gain of the animals was unaffected by Si supplementation (Supplemental Figure 
2; p > 0.2 for female rats and p > 0.4 for male rats). There was also no association between 
serum Si and body weight or body weight gain (r = - 0.2, p > 0.5). Moreover, no adverse 
effects (clinically, biochemically or pathologically) were associated with three months’ 
MMST supplementation at either the moderate or high doses investigated (data not shown), 
consistent with previous findings in a lower dose, 4-week human supplementation study [10]. 
 
Tissue silicon measurements 
A dose-responsive increase in Si concentrations of the serum and collagen-rich ear tissue was 
apparent with Si supplementation (p < 0.05, test for linearity; Figure 1a & 1b). However, for 
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the tibia, there was not a dose response: whilst the moderate dose of supplemental Si led to a 
significant increase in bone Si levels (p = 0.03) the high dose had no effect (Figure 1c). 
Similar patterns were observed for male and female rats (data not shown). 
 
Bone associated elements 
Serum Cu and Zn concentrations were significantly increased in female rats on moderate dose 
Si supplementation and a similar, but non-significant, trend was seen for tibia Cu and Zn 
levels (Supplemental Tables 2 & 3). Male rats showed a similar trend for serum and tibia Cu 
levels (Supplemental Tables 2 & 3). Moreover, in the female rats, tibia Ca and tibia Ca:P 
ratios were increased with the high dose of Si compared to controls (p = 0.025 and 0.016 
respectively; Figure 2), while in male rats no statistically significant differences in tibia 
concentrations of Ca, P or Ca:P were found with Si supplementation (p > 0.1 compared to 
controls; data not shown).  
 
Serum Osteocalcin 
Serum osteocalcin concentrations were similar in female and males rats (p = 0.45) but in 
female rats there was a trend for a dose dependent increase in osteocalcin concentration with 
Si supplementation (Figure 3). Moreover, although serum osteocalcin concentrations showed 
no correlation with serum Si concentrations in female rats (p = 0.3), strong negative 
correlation was seen in male rats (r = -0.72, p = 0.008).  
 
Bone quality measures 
Silicon supplementation had no effect on tBMD in male rats (Figure 2d & Supplemental 
Table 4) and, although mean tBMD increased for female rats, it was not significant either 
(Figure 2D & Supplemental Table 4). Nonetheless, given the relatively low group numbers 
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and the variance around serum and bone Si levels, we considered that an association between 
Si levels and tBMD could have been masked by categorical analysis. To this end direct 
correlations showed a strong relationship between fasting serum Si levels (a recognised proxy 
for Si status (10)) and tBMD in female rats but not in male rats (Figure 4a vs. 4b). Bone Si 
levels also correlated with tBMD for female rats only (Figure 4c vs. 4d), albeit not as strongly 
as between serum Si and BMD and perhaps explained by the association between serum Si 
and bone Si levels (Figure 4e & 4f). 
Moreover, fasting serum Si concentrations were found to correlate strongly with other 
bone quality measures and, again, only for the female rats. Associations were positive with 
BV/TV, BS/TV and with Tb.N, and negative with Tb.Sp and Po(T) (Figure 5). Strong 
positive correlations were also obtained for fasting serum Si levels and, individually, BV (r = 
0.79, p = 0.0008) and BS (r = 0.72, p = 0.004) but not TV (r = − 0.06, p = 0.835) or TS (r = 
0.02, p = 0.934). So serum Si in female rats was associated with the amount of bone, but not 
the size of bone. A weaker (positive) correlation was obtained with Tb.Th (r = 0.64, p = 
0.014).  
The above correlations were also generally found with tibia Si levels but, again, were 
not as significant as for the fasting serum Si levels (data not shown). In the single indicator 
tibia samples taken from each group for ex-vivo X-ray diffraction analyses there was no 
suggestion that Si supplementation altered bone mineral phase (Supplemental Figure 3). 
Silicon intervention did not significantly altered bone strength based upon categorical analysis 
(Supplemental Table 5) whilst, unlike for tBMD, the positive correlation with serum Si was 
not significant (Figure 5f-h). 
Finally, to address the specificity of silicon’s association with bone quality, we next 
assessed correlations of other serum (n = 5) and tibia (n = 8) elemental concentrations with 
tBMD (see methods). Of these only serum Mg yielded a (weak) correlation with tBMD (r = 
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0.64, p = 0.015 in female rats and r = 0.61, p = 0.016 in male rats), but this did not carry 
through with any other bone quality measures (data not shown). 
It should be noted that in female rats, serum estradiol showed no correlations with 
serum Si, tibia Si, serum osteocalcin or tBMD (Supplemental Table 6). A significant 
correlation was obtained with TbTh (r = -0.67, p = 0.05; data not shown), but this was in the 
opposing direction to serum Si. In male rats serum estradiol showed no association with bone 
quality measures, although significant association with serum osteocalcin (r = 0.71, p = 0.033) 
and Fy (r = -0.88, p = 0.004) were obtained (Supplemental Table 6).  
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Discussion  
As noted above we have previously reported, in human epidemiological studies, a strong 
positive association between dietary Si intake and BMD in pre-menopausal women [3,4], 
whilst the lack of association in post-menopausal women was restored for those taking 
hormone replacement therapy [4]. We thus proposed that the dietary Si-BMD effect is 
estradiol mediated [3]. Assuming that Si has some active beneficial role in human and other 
mammalian connective tissues then these prior studies [3,4], and other data [1], indicate that 
the chemical species responsible is almost certainly orthosilicic acid (Si(OH)4). Dietary Si 
appears to be absorbed only in monomeric form from the gastrointestinal tract [12,19], either 
directly so from fluids such as drinking water, or, following digestion of plant-based foods. 
For these reasons the CRO-based three month supplementation study that is described herein 
provided an excellent opportunity to test the hypothesis that dietary Si positively impacts 
BMD in estradiol-replete mammals. Firstly, unlike orthosilicic acid which starts to form 
insoluble silicates much above 56 mg Si/L (2 mM Si), MMST (CH3Si(OH)3) may be added to 
drinking water at up to 588 mg Si/L (21 mM Si) without irreversible polymerisation and 
precipitation. Moreover, MMST appears entirely non-toxic, again as confirmed herein, and is 
metabolised to orthosilicic acid in vivo [10]. Secondly, in murine models a three-month time 
period should be sufficient time to see the impact on BMD of effective intervention [20]. 
Thirdly, male and female rats differ in their circulating estradiol levels by 1.7 fold in this 
study and by even greater amounts in prior studies [8,9].  
Fasting serum concentrations of Si provide the best known measure of Si status because 
recently ingested and absorbed Si is rapidly cleared from the circulation and, hence, fasting 
levels provide a steady state measure of Si that is presumed to be in equilibrium with body 
stores [10]. The finding that, following intervention, fasting serum Si levels were strongly 
positively correlated with trabecular BMD in female rats but not male rats supports the 
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hypothesis that estradiol is required for the in vivo beneficial utilisation of Si. Of course other 
hormonal differences between male and female rats (i.e. other than estradiol) may explain or 
contribute to these findings. However, a previous study that looked at the effects/contribution 
of the different sex and endocrine hormones on the absorption of Si and tissue Si levels in 
adult rats found that estrogen deficiency in female and male rats produced the most 
pronounced effects [5], suggesting that estradiol may be the main or most potent mediator of 
Si metabolism. Similarly, with regards to bone, estrogen deficiency has the most marked 
effect on bone growth in male and female rats [21]. Replication of our findings in intact 
(sham-operated) and estradiol–supplemented ovariectomised rats but not in ovariectomised 
rats would provide the best proof for this, because, as mentioned above, in our previous 
observational study, the Si-BMD relationship was regained in post-menopausal women who 
were taking HRT [4].  
Whether there is a small effect of oral Si on tBMD in male rats, as is observed for 
dietary Si–BMD associations in male humans [3], would probably require greater study 
numbers for intervention than we had access to in this work. It is also possible that in male 
rats Si supplementation affects a different bone compartment: i.e. cortical bone rather than (or 
more than) trabecular bone. Cortical bone thickness was not measured in this study and 
biomechanical data (which mainly evaluates cortical bone properties; see below) was 
incomplete for male rats (Supplemental Table 5). To our knowledge the effects of Si 
supplementation on cortical and trabecular bone compartments have not been directly 
evaluated in the literature even though, our previous epidemiological study showed similar Si-
BMD associations at the different hip sites and the lumbar spine in men [3], implying that Si 
may affect both bone compartments equally. 
How dietary Si could promote BMD in ‘estradiol-replete’ mammals is presently 
unclear, although additional observations herein may provide some clues. For example, tibia 
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Si levels showed some correlation with tBMD and other bone quality measures but these were 
either not significant or were weak compared to the serum Si correlations with BMD. This 
suggests that the Si effect is not due to and/or sensed from direct incorporation of Si into bone 
but, rather, is a peripherally-generated signal as previously argued [16]. Indeed, although only 
three bone samples were analysed by XRD, there was certainly no obvious change to bone 
mineral with Si supplementation. This is not surprising, as the highest increase in bone Si 
content, with Si supplementation, was < 0.01 atomic mole % and thus unlikely to directly 
affect the mineral phase or its properties. In fact, tibia Si levels did not increase linearly with 
Si supplementation (Figure 1). This was not a result of the higher dose being less 
bioavailable, as indicated by the increase in fasting serum and ear tissue Si levels compared to 
the moderate Si dose groups. It is more likely that it indicates a safety mechanism: a negative 
feedback to protect against marked changes in bone composition and/or over mineralisation, 
which could affect bone quality and bone strength, as suggested by Reffitt et al. [22] and 
consistent with our more recent data [16,23]. Together, these findings suggest that different 
tissues could have differing Si tolerances/requirements and, in bone, this may have been 
surpassed with the high Si dose albeit not for the collagenous ear tissue. However, to confirm 
this, additional doses of Si/MMST should be tested. 
The specific strong correlations between serum Si concentrations and bone quality 
measures, and the lack of similar correlations between serum estradiol with either bone 
quality measures or with serum Si concentrations, suggest that the effect of Si is not directly 
through estradiol or changes in estradiol concentrations. As such the findings suggest that 
estradiol mediates the effect of Si rather than vice versa. 
The positive association between fasting serum Si concentration and tBMD in female 
rats was backed up by strong correlations with other bone quality measures (Figure 5) and the 
trend for a dose-dependent increase in serum osteocalcin concentration. Overall serum Si in 
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the female rats correlated positively with the amount of bone tissue (BV, BS, BV/TV, BS/TV, 
Tb.Th and Tb.N) and negatively with the amount of non-bone tissue/space (Tb.Sp and Po(T)), 
i.e. suggesting that Si supplementation is associated with increased bone tissue within the 
volume measured. These findings did not, however, proceed to a correspondingly significant 
increase in bone strength. There are two possible explanations. Firstly, it is possible for BMD 
to be increased without an increase in bone strength/bone stiffness. For example, the addition 
of bone to the endocortical surface of female rats does not lead to an increase in bone strength 
[21]. Female rats have higher BMD compared to male rats, but this is not associated with 
higher bone stiffness/bone strength and is in fact associated with lower bone stiffness/bone 
strength than male rats ([21]; Supplementary Tables 4 & 5). The second possibility is that Si 
affects trabecular bone (and therefore tBMD) but not cortical bone in female rats. The three-
point bending test evaluates the shaft of the bone, i.e. cortical bone properties (e.g. cortical 
thickness and cross-sectional area). Hence, it is possible that Si could change bone micro-
architecture without effects on bone stiffness as assessed by three-point bending. The lack of 
correlation between tBMD and bone strength measures here supports this statement (data not 
shown). 
Finally, these data also show specificity in the association with tBMD to Si as the other 
serum and tibia elements investigated (including Cu, Zn, Mg, Ca, P and Ca:P ratio), either 
showed no correlation with bone quality measures or were markedly weaker (data not 
presented), regardless of gender. In female rats the weak correlations observed for serum Mg 
concentrations with tBMD (r = 0.64, p = 0.015), BS/TV (r = 0.53, p = 0.051), TbN (r = 0.53, 
p = 0.053), and Po(T) (r = -0.55, p = 0.044), and for serum P concentrations with BV/TV (r = 
0.54, p = 0.046) and Po(T) (r = -0.54, p = 0.046), are most likely driven by their associations 
with serum Si concentrations (r = 0.63, p = 0.016 for serum Mg and r = 0.57, p = 0.035 for 
serum P). Silicon supplementation increased serum and tibia Cu concentrations in both male 
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and female rats, and serum and tibia Zn concentrations in female rats. Similar findings have 
previously been reported. Emerick & Kayongo-Male [24] reported that Si supplementation 
increased the Cu status (plasma Cu concentrations) of both Cu-deplete and Cu-replete rats 
while, more recently, Seaborn & Nielsen [25] reported that Si deprivation reduced femoral 
and vertebral rat bone Cu and Zn concentrations. Emerick & Kayongo-Male [24] went further 
to suggest that some of the reported effects of Si (on connective tissues) may be attributed to 
an increase in Cu utilisation. However, as noted above, we did not find any correlations 
between serum or tibia Cu concentrations with bone quality measures, but we did with serum 
Si, suggesting that, at least here, the Si effect on bone quality was not driven by the increase 
in Cu utilisation.  
Previous studies have shown that when the bone steady-state (equilibrium) is 
challenged, such as with ovariectomy, osteopenia or reproduction, oral or intravenous Si 
intervention can help maintain BMD [26-31] (see also reviews by Jugdaohsingh [1] and Price 
et al. [32]). In the work presented here, however, the rats were healthy. Moreover, the rats 
were not Si deficient so the effects seen are not the correction of a state of stress but, rather, 
are offering insights into ‘optimal nutrition’. The supplemental dosing undertaken in this 
study was, primarily, for regulatory safety assessment purposes and, therefore, the doses were 
high. In the ‘moderate’ dose group, 115 mg Si/L (4.1 mM MMST) was the sole source of 
fluid. In adult human supplementation it would be just 90 mL/day out of, typically, 2 L total 
fluid intake per day [10]. The ‘high’ dose group was the same except the Si concentration was 
575 mg Si/L (20.5 mM MMST) instead of 115 mg/L. Translating these findings to human 
intakes of Si is not easy. On the one hand, as noted above, supplementation in the rats was 
disproportionately high compared to human dosing. On the other hand, nutrient intakes are 
always disproportionately high for rats versus humans [33] and the Si supplementation of this 
study only increased the rats naturally high dietary Si intake by 18.0% and 99% with 
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moderate and high dosing respectively. Interestingly, by analogy, the correlation between 
dietary Si intake and BMD in pre-menopausal women of the Framingham cohort [3] shows no 
tail-off in the relationship at the upper quintile of Si intake (30-63 mg/day), so perhaps 
optimal dietary Si intakes in pre-menopausal women could indeed be higher.  
 
Conclusion 
In conclusion, this paper reports that Si supplementation increases fasting serum and 
connective tissue Si concentrations in rats. In female rats, concentrations of serum Si, but not 
other bone or serum elements, correlated strongly with trabecular BMD and other bone 
quality measures. These relationships were not seen in male rats and were not seen with 
measures of soft tissue quality for either gender, supporting the hypothesis that estradiol is 
required for the optimal utilisation of dietary Si in bone/connective tissues. However, 
additional animal models (e.g. estrogen receptor knockouts (ER-null) or ovariectomy with 
and without estradiol) are required to confirm this. The effect appears to be related to 
systemic signalling, governed by steady state circulating Si levels, rather than direct 
incorporation of Si into bone. Further work should also aim to identify the mechanism.  
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Table 1. 
Mean daily silicon intakes from drinking watersa 
   Female rats    Male rats  
 
 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L  
(n=5) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L  
(n=5) 
Drinking water (ml/day)b  21.5 (2.2) 22.9 (3.9) 26.5 (3.1)d  29.9 (3.0) 29.0 (5.4) 29.4 (4.7) 
Si intake from water (mg/d)c  < 0.002 2.64 (0.45) 15.21 (1.77)  < 0.002 3.33 (0.62) 16.86 (2.71) 
a Means (± SD) calculated from daily measurements between days 40 and 50. Feed intake was not measured but was estimated to be 23 g/d in 
female rats and 32 g/day in male rats, contributing ~ 14 and 19 mg Si/d, respectively in female and male rats. 
b A vehicle control (reverse osmosis treated drinking water with < 0.1 mg Si/L) or Si-supplemented drinking water (115 mg Si/L or 575 mg Si/L) 
was consumed by the animals ad libitum as a substitute for normal drinking water. 
c There was no significant difference in Si intake between female and male rats. 
d Intake was significantly greater than control (p = 0.02, unpaired T-test). 
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Figure legends 
Figure 1. Fasting silicon concentrations in the tissues of rats (n=10 per treatment: 5 males and 
5 females), in the control and Si-supplemented groups, collected at necropsy (i.e. after 12 
weeks intervention). Data is shown as box-plots where the horizontal lines indicate the 5th, 
25th, 50th (i.e. median), 75th and 95th percentiles, the open square shows the mean and the 
crosses the minimum and maximum values. Test for linearity was significant for serum Si (p 
< 0.05) and ear Si (p < 0.0001) concentrations, but not tibia Si concentration (p = 0.17). By 
subsequent t-test of the tibia, p = 0.003 for 115 mg Si/L vs. Control and was not significant 
for 575 mg Si/L versus control.  
 
Figure 2. Calcium (a), phosphorus (b) and Ca:P (c) concentrations of the tibias of female rats 
(n=5 per treatment), in the control and Si-supplemented groups, at necropsy after 12 weeks 
supplementation. (c) Trabecular bone mineral density (tBMD) of the tibia of male and female 
rats at necropsy. Data is shown as box-plots where the horizontal lines indicate the 5th, 25th, 
50th (i.e. median), 75th and 95th percentiles, the open square shows the mean and the crosses 
the minimum and maximum values. Tibia calcium concentration and Ca:P ratio were higher 
in the higher dose Si group, compared to the diluent control (p = 0.025, for the 575 mg Si/L 
vs. Control; unpaired T-test). 
 
Figure 3. N-mid osteocalcin concentrations of the fasting serum, collected at necropsy, of the 
female (a; n=4 per treatment) and male (b; n=4-5 per treatment) rats, in the control and Si-
supplemented groups after 12 weeks supplementation. Data is shown as box-plots where the 
horizontal lines indicate the 5th, 25th, 50th (or median), 75th and 95th percentiles, the open 
square shows the mean and the crosses the minimum and maximum values. 
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Figure 4. (a & b) Associations between fasting serum silicon concentrations and trabecular 
bone mineral density (tBMD) of the tibias of female (a) and male (b) rats at necropsy (12 
weeks intervention) (r= 0.90 & p < 0.0001 for the female rats; Pearson Correlation with 2-
Tailed T-test). (c & d) Associations between tibia Si concentrations and tBMD in female (c) 
and male (d) rats at necropsy (r = 0.47 & p = 0.074 for the female rats; Pearson Correlation 
with 2-Tailed T-test). (e & f) Associations between fasting serum Si concentrations and tibia 
Si contents of the female (e) and male (f) rats at necropsy (r= 0.47 & p = 0.093 for the female 
rats; Pearson Correlation with 2-Tailed T-test). Note, the correlation reported in a was not 
dependent upon the serum Si value at 532 µg/L as its removal from the dataset only 
marginally affected the correlation reported; i.e. was still highly correlated (r = 0.8, p = 
0.002). 
 
Figure 5. Associations between fasting serum silicon concentrations and bone 
microarchitecture/quality of female rat tibias collected at necropsy (12 weeks intervention). 
Positive correlations were obtained for (a) bone volume fraction BV/TV (r = 0.90 & p < 
0.0001; Pearson Correlation with 2-Tailed T-test), (b) bone surface density BS/TV (r = 0.91 
& p < 0.0001; Pearson Correlation with 2-Tailed T-test), (c) trabecular number Tb.N (r = 0.90 
& p < 0.0001; Pearson Correlation with 2-Tailed T-test), while negative correlations were 
with (d) trabecular separation Tb.Sp (r = -0.80 & p = 0.001; Pearson Correlation with 2-
Tailed T-test) and (e) total porosity Po(T) (r= -0.90 & p < 0.0001; Pearson Correlation with 2-
Tailed T-test). Correlations between fasting serum Si concentrations and bone stiffness (f), 
yield strength (g) and fracture load (h) were not significant; r = 0.15, 0.27 and 0.41 and p = 
0.6, 0.4 and 0.1, respectively. The correlations reported are not dependent upon the serum Si 
value at 532 µg/L, as its removal from the dataset only marginally affected the correlations 
reported; i.e. all were still highly correlated (r = 0.8, p < 0.004). 
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Supplemental Materials and Methods 
More thorough methodological details on the analyses performed in the paper are given 
below. 
Materials 
For sample analysis, ultra high purity (UHP) water was 18 MΩ/cm, from a Branstead Nano-
Pure water purifier (Thermo Scientific; Ohio, USA). Nitric acid (69% (w/v) p.a. plus) was 
high purity from Fluka Ltd (Gillingham, UK). Hydrogen peroxide (30%, Suprapure), Si ICP 
stock standard solution (1000 mg/L Si), diethyl ether (AnalaR grade) and microcentrifuge 
tubes (1.5 mL) were from VWR Ltd (Poole, UK). Polypropylene (PP) tubes (13 mL & 50 
mL) were from Sarstedt Ltd (Leicester, UK). Rat N-Mid Osteocalcin ELISA kit was from 
MyBioSource Inc (Sand Diego, USA). 17β-estradiol high sensitivity ELISA kit was from 
Enzo Life Sciences UK Ltd (Exeter, UK). 
 
Assays 
Serum 17β-estradiol 
Fasting serum samples were analysed for 17β-estradiol to confirm the higher circulating 
serum levels in female rats compared to male rats and to investigate potential changes in 
circulating levels with Si treatment. Aliquots (150 µL) of the undiluted sera underwent liquid-
liquid extraction with diethyl ether (750 µL) and then the extracts were air dried and 
reconstituted in 110 µL assay buffer (supplied in the ELISA kit). Samples were analysed 
using the 17β-Estradiol high sensitivity ELISA kit, following the kit’s protocol. Absorbance 
was read at 405 nm using an optical microplate reader (LabSystems Multiskan RC). 
 
Serum osteocalcin 
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The fasting serum samples were also analysed for osteocalcin, a marker of bone 
formation/bone turnover, using the commercially available Rat N-Mid Osteocalcin kit. 
Aliquots (100 µL) of the undiluted sera were used and the assay was carried out as per the 
instructions given in the kit protocol. Absorbance was read at 450 nm (detection wavelength) 
and 595 nm (correction wavelength) using an optical microplate reader (LabSystems 
Multiskan RC; Thermo Scientific, USA). 
 
Total elemental analysis 
Total elemental analyses were carried out by inductively coupled plasma optical emission 
spectrometry (ICP-OES), Jobin Yvon 2000-2 (Instrument SA, Longjumeau, France), 
equipped with a concentric nebuliser and cyclonic spray chamber. The sample flow rate was 1 
mL/min. Peak profiles were used as previously described [12,14], with a window size of 0.08 
nm (0.04 nm either side of the peak) with 21 increments per profile and an integration time of 
0.5 second per increment. Analytical lines were: 251.611 nm (Si), 213.618 nm (phosphorus, 
P), 315.887 nm (calcium, Ca), 279.806 nm (magnesium, Mg), 766.490 nm (potassium, K), 
213.856 nm (iron, Fe), 257.610 nm (zinc, Zn), 259.940 nm (manganese, Mn) and 324.754 nm 
(copper, Cu). 
Accurate iron levels in serum are unreliable with this methodology due to lysed 
erythrocyte contributions of haem iron, which occurs even with invisible haemolysis [15]. 
Similarly, phosphate cannot be measured in this fashion as total serum phosphorus includes 
significantly more than just inorganic phosphate. Hence, these two elements were excluded 
from serum analysis but were maintained for bone analysis. All samples were analysed in a 
blinded fashion. 
 
Serum samples 
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An aliquot of the blood samples collected with 20 gauge needle and syringe (5 & 10 mL) was 
collected into 13 mL polypropylene (PP) tube and allowed to clot at 4°C without 
anticoagulants. The clotted blood samples were centrifuged at 4°C in a refrigerated centrifuge 
(Labofuge 400R) and the separated serum collected in a clean 13 mL PP tube and stored at -
80°C prior to being couriered on dry ice to the authors. Serum samples were analysed using 
methods previously described [16]. 1 mL aliquot was diluted 1+4 with 0.2% nitric acid 
(prepared by diluting 69% nitric acid in UHP water) in 13 mL PP tubes. After through 
mixing, 2 mL from each of the diluted sera samples was removed and pooled into a 50 mL PP 
centrifuge tube. Pooled sample based standards were prepared by spiking aliquots of the 
pooled diluted sera with Si (0-1 mg/L). Aqueous silicon standards (0-1 mg/L Si) were also 
prepared, in 0.2% nitric acid, to determine the Si content of the acid diluent. Diluted sera and 
acid diluent (0.2% HNO3) were analysed with their appropriate set of standards in a single 
batch. For analysis of the other serum elements, the serum samples were diluted 50-fold in 
0.2% nitric acid. Analysis was carried out in a blinded fashion, using appropriately prepared 
pooled, multi-element, sample-based standards (0-10 mg/L of each element). Serum 
manganese concentrations could not be assessed as concentrations in the diluted samples were 
not different to the acid diluent alone. 
 
Ears 
Ears were analysed for Si content as a source of non-articulating, non-calcified 
collagenous tissue and, thus, potential site of Si utilisation. One of the pair of ears from each 
animal was cleaned of excess hairs, washed in high-purity water, blotted dry and placed in 
pre-weighed 13 mL PP tubes. The mass was determined and then samples digested with 2.5 
mL of a 1+1 mixture of concentrated nitric acid (69% pa plus) and 30% hydrogen peroxide. 
Sample blanks were similarly prepared. Samples and sample blanks were placed overnight in 
Supplementary Data 
31 
a shaking incubator (HT Infors Minitron; Infors AG, Basel, Switzerland) set at 81 rpm and 
45°C to digest. Upon complete digestion, the samples and sample blanks were diluted with 2 
mL UHP water. One ml was then removed from each of the diluted samples and pooled in a 
50 mL PP centrifuge tube. Pooled sample based standards were prepared by spiking aliquots 
of the pooled diluted sample with Si (0-10 mg/L). Aqueous acid-based Si standards (0-10 
mg/L Si) were also prepared, in 19% nitric acid, to determine Si content of the sample blanks. 
The diluted samples and sample blanks were analysed in a blinded fashion for total Si content 
with their appropriately prepared standards all in a single batch. 
 
Tibias 
Tibias were digested and analysed using previously described methods [16]. One of the 
pair of tibias from each animal was cleaned of soft tissue, ligaments and tendons and then 
digested separately in 10 mL (females) or 12 mL (males) of an acid-water mixture consisting 
of: one part nitric acid (69% p.a. plus) and three parts UHP water. Samples were digested at 
185°C (10 min ramp to 185°C and maintained at 185°C for 20 min) in acid-cleaned TFM 
vessels in a Milestone Ethos Plus microwave digestion system (Milestone Srl, Sorisole, Italy). 
This method gives a complete digestion of the bone samples (i.e. both the organic and 
inorganic components are digested). Digested samples were transferred to pre-weighed 13 mL 
PP tubes to determine final digest volumes and for ICP-OES analysis. Sample blanks were 
similarly prepared but without samples. Total Si analysis of the samples was carried out using 
sample-based standards (0-10 mg/L Si) prepared in aliquots of a pooled sample of the 
digested bones (1mL was removed from each of the digested bones for the final pool). Sample 
blanks were analysed with standards (0-10 mg/L Si) that were prepared in the acid-water 
mixture. All samples, including sample blanks, were analysed in a single batch. The digest 
samples and sample blanks were also analysed for Mn and Cu concentrations in a similar 
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fashion but further diluted in UHP water for the determination of other elements: 10-fold 
dilution for Zn, Fe and K concentrations; 100-fold dilution for Mg concentrations; and 1,000-
fold dilution for Ca and P. Analysis was carried out using appropriately prepared sample-
based standards in a blinded fashion.  
 
Rodent feed 
Samples (0.1 g; n=4) of the rat feed were digested with 5 mL of 1:1 mixture of 69% 
nitric acid and UHP water at 185°C (for 25 min, following a 15 min ramp to 185°C) in the 
Milestone Ethos Plus microwave digestion system. Ten mL UHP water was added to each 
sample at the end of the digestion run. Sample blanks (n=4) were similarly prepared. The 
digested samples and sample blanks were analysed in a blinded fashion for Si and other 
elements in a single batch with appropriately prepared multi-element sample-based standards 
(0-10 mg/L Si and other elements).  
 
Bone quality measurements 
The second of the pair of tibias collected from each animal at necropsy was cleaned as 
described above at the authors’ laboratory and couriered, frozen on dry ice, from the authors’ 
laboratory to the Laboratory of Pathophysiology, University of Antwerp, Belgium for micro-
CT analysis. For analysis the bone samples were moistened in physiological saline and 
wrapped in parafilm to avoid reflection artefacts, as recommended for BMD measurement by 
the micro-CT manufacturer. Scans were performed on a SkyScan 1076 in-vivo X-ray micro-
CT scanner (Aartselaar, Belgium) equipped with software version 3.2 (build 2) and a 
Hamamatsu Orca-HRF camera with pixel size of 11.74 µm. A scanning width of 35 µm and 
Image Pixel Size of 34.72 µm were used. Each tibia was scanned once and each scan 
consisted of 300 images: four images were collected and averaged at each 0.6° rotational step 
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over a 180° rotation of the bone. The resolution of the measurements was 35 µm. After 
reconstruction of the images, a number of bone quality (microarchitecture) parameters 
(measures) were derived, including: trabecular BMD (tBMD, g/cm3), tissue volume (TV, 
µm³), bone volume (BV, µm³), bone volume fraction (BV/TV, %; the proportion of the total 
volume occupied by mineralised bone), total surface (TS, µm²), bone surface (BS, µm²), bone 
surface/volume ratio (BS/BV, 1/µm), bone surface density (BS/TV, 1/µm), trabecular 
thickness (Tb.Th, µm), trabecular separation (Tb.Sp, µm), trabecular number (Tb.N, 1/µm) 
and total porosity (Po(T), %). Trabecular BMD was determined from a calibration curve 
produced with phantom bones of specific BMD and due to shadow effects an error of ± 10 
mg/cm3 can be expected on these measurement. Trabecular separation and trabecular number 
were calculated separately, directly from the scans: i.e. they are not derived from each other. 
Total porosity is the sum of the open and closed pores and thus is a measure of the 
canalisation of the trabeculae. Samples were again analysed in a blinded fashion.  
 
X-ray diffraction 
One tibia from each of the groups of the female rats that had undergone micro-CT analysis 
underwent powder XRD analysis at the Institute for Materials Research, University of Leeds 
(UK). Prior to analysis the bones were crushed with a mortar and pestle, freeze dried and 
subjected to several solvent extractions (based on the method by Kim et al., (17)) to remove 
organic components from the bone matrix that could interfere with the XRD analysis: namely, 
2:1 chloroform/methanol mixture (for 3 h at 4°C, ×3), ice-cold methanol rinses (×3), 6 M 
guanidine HCl in methanol (overnight at 4°C), ice cold methanol and ice cold ethanol rinses 
(×3). The bone samples were then dried overnight at 60°C in a dry oven before further 
grinding with a mortar and pestle and oxygen plasma ashing (10 W for 15 min, × 10 cycles in 
an Emitech K1050X Plasma Asher; Quorum Technologies Ltd, Ashford, UK). Fourier Infra-
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Red analysis (Shimadzu IRPrestige-21 FT IR; Shimadzu, Kyoto, Japan) confirmed removal of 
much of the organic constituents in the bone matrix without any significant changes to the 
bone mineral. X-ray diffraction data were collected using a P’Analytical X’Pert MPD 
employing Cu Kα1+2 radiation (Almelo, The Netherlands). The bone powders were sieved 
through a 300 micron gauze onto a low-background-Si substrate, and rotated during 
collection. The sample was scanned in the range 10 < 2θ < 80, in steps of 0.05°, for a total 
time of ca. 1 h. Programmable divergence and anti-scatter slits were used, with an irradiated 
area of 15 x 15 mm. XRD analysis was also carried out in a blinded fashion. Formal statistical 
comparisons were not intended as only one ‘indicator’ tibia per group was analysed, and this 
was only in case supplemental silicon had been highly loaded into bone yielding obvious 
spectral differences in bone quality. 
 
Biomechanical testing 
Tibias from female rats were subjected to three-point bending test at room temperature in a 
custom made loading device, integrated in a materials testing machine (Bose ElectroForce 
Test Bench LM1, Bose Corp, USA). The fibula was removed and tibia placed with the lateral 
surface facing down. Load was applied midway between two supports 1.00 mm distal and 
14.0 mm proximal from the tibia-fibula junction. A stabilising preload was applied (ramped to 
4 N at 0.2 N/s) followed by five conditioning cycles (oscillating between 4 N and 24 N at 0.05 
Hz), dwell at 4 N for 5s, and finally loading until failure at a rate of 0.05 mm/s. It was verified 
a posteriori for all samples that the load of 40 N was located within the linear region of the 
force displacement (F–δ) curve. From the F–δ curves the following parameters were 
calculated: stiffness (k; N/mm) was determined as the slope of the force–displacement curve 
at 40 N load; yield strength (Fy; N) was determined as the load where the tangent to the F–δ 
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curve fell to 95% of the stiffness k; fracture load (Fmax; N) was defined as the maximum load 
sustained by the structure. Analysis was carried out in a blinded fashion.  
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Supplementary Table 1. Element concentrations of the 2018 Teklad 18% Protein Rodent 
diet determined by analysis herein 
Elements Mean SD 
Ca (mg/g) 8.391 1.053 
P (mg/g) 6.46 0.104 
K (mg/g) 7.572 0.052 
Mg (mg/g) 2.473 0.056 
Si (µg/g) 610.4 97.3 
Fe (µg/g) 195.9 22.0 
Zn (µg/g) 76.7 15.01 
Mn (µg/g) 85.56 8.43 
Cu (µg/g) 15.40 2.87 
B (µg/g) 8.852 2.653 
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Supplemental Table 2. Fasting serum element concentrations in the control and Si-supplemented groups after 12 weeks intervention 
 Combined (Males & Females)   Female rats    Male rats  
 
Serum  
Elements 
Group 1: 
Control 
(n=10) 
Group 2: 
115 mg Si/L 
(n=10) 
Group 3: 
575 mg Si/L 
(n=9) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=4) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L  
(n=5) 
Ca (mg/L) 85.8 (4.1) 87.6 (4.5) 88.1 (2.3)  86.2 (3.1) 90.4 (4.5) 88.2 (1.6)  85.4 (5.3) 84.7 (1.9) 88.1 (2.9) 
Mg (mg/L) 22.7 (3.3) 23.2 (2.9) 21.5 (1.0)  22.8 (3.0) 24.9 (1.4) 21.3 (1.3)  22.6 (4.0) 21.6 (3.2) 21.8 (1.0) 
K (mg/L) 323 (46) 315 (21) 325 (20)  294 (37) 315 (32) 315 (18)  361 (19) 315 (12)d 334 (19) 
Zn (mg/L) 1.27 (0.21) 1.28 (0.10) 1.28 (0.08)  1.09 (0.10) 1.34 (0.10)a 1.22 (0.02)b  1.45 (0.09) 1.22 (0.06)e 1.33 (0.07)f 
Cu (mg/L) 0.83 (0.25) 0.98 (0.38) 1.07 (0.26)  0.98 (0.23) 1.33 (0.19)c 1.12 (0.21)  0.65 (0.12) 0.70 (0.20) 1.02 (0.32) 
Means (± SD) of samples collected at necropsy.  
aP= 0.004, bP= 0.043, cP= 0.045, dP= 0.003, eP= 0.002, fP=0.047, gP= 0.032; vs. control (Student t-test).  
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Supplemental Table 3. Element concentrations in the tibia of rats in the control and Si-supplemented groups after 12 weeks intervention 
 Combined (Males & Females)   Female rats    Male rats  
 
Tibia 
Elements 
Group 1: 
Control 
(n=10) 
Group 2: 
115 mg Si/L 
(n=10) 
Group 3: 
575 mg Si/L 
(n=10) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=5) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=5) 
Ca (mg/g) 153 (7) 156 (13) 158 (9)  158 (4) 164 (13) 165 (5)c  147 (6) 147 (5) 151 (5) 
P (mg/g) 86.1 (7.3) 88.9 (9.3) 88.5 (5.7)  92.5 (3.5) 95.6 (8.8) 92.8 (3.7)  79.8 (2.9) 82.3 (2.5) 84.2 (3.5) 
Mg (mg/g) 3.20 (0.22) 3.36 (0.31) 3.36 (0.12)a  3.35 (0.16) 3.55 (0.33) 3.39 (0.10)  3.05 (0.14) 3.17 (0.15) 3.33 (0.14)e 
K (mg/g) 1.27 (0.29) 1.17 (0.38) 1.25 (0.29)  1.13 (0.36) 1.00 (0.48) 1.10 (36)  1.41 (0.11) 1.35 (0.13) 1.39 (0.11) 
Zn (µg/g) 199 (19) 207 (32) 197 (17)  214 (15) 232 (27) 211 (7)  185 (10) 183 (11) 182 (8) 
Fe (µg/g) 49.6 (12.6) 53.6 (6.6) 48.6 (10.3)  48.2 (8.9) 55.8 (7.1) 55.6 (9.5)  50.9 (16.6) 51.5 (6.2) 41.6 (5.1) 
Cu (µg/g) 1.45 (0.14) 1.70 (0.31)b 1.56 (0.17)  1.52 (0.14) 1.60 (0.12) 1.47 (0.06)  1.38 (0.10) 1.81 (0.42) 1.64 (0.22)f 
Mn (µg/g) 0.69 (0.10) 0.75 (0.09) 0.73 (0.08)  0.78 (0.06) 0.78 (0.05) 0.75 (0.04)  0.61 (0.05) 0.72 (0.11) 0.71 (0.11) 
Ca:P 1.79 (0.09) 1.76 (0.06) 1.79 (0.03)  1.71 (0.04) 1.72 (0.06) 1.78 (0.03)d  1.85 (0.06) 1.80 (0.03) 1.79 (0.04) 
Means (± SD) of samples collected at necropsy.  
aP= 0.05, bP= 0.029, cP= 0.026, dP= 0.016, eP= 0.013, fP=0.043; vs. control (Student t-test). 
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Supplemental Table 4. Bone microarchitecture (quality) of rats in the control and Si-supplemented groups 
 Combined (Males & Females)   Female rats    Male rats  
 
 
Tibia 
Group 1: 
Control 
(n=10) 
Group 2: 
115 mg Si/L 
(n=10) 
Group 3: 
575mg Si/L 
(n=10) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=5) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=5) 
tBMD (g/cm3) 0.316 (0.155) 0.327 (0.136) 0.319 (0.155)  0.440 (0.115) 0.453 (0.016) 0.453 (0.088)  0.193 (0.053) 0.201 (0.043) 0.184 (0.028) 
BV (mm3) 1.67 (1.03) 1.69 (0.68) 1.96 (1.19)  2.10 (1.30) 2.12 (0.64) 2.63 (1.34)  1.24 (0.46) 1.26 (0.42) 1.29 (0.50) 
TV (mm3) 32.8 (14.1) 32.5 (12.4) 35.2 (12.9)  20.5 (3.4) 21.9 (5.9) 23.3 (2.6)  45.0 (7.7) 43.0 (5.8) 47.0 (4.2) 
BS (mm2) 88.4 (44.6) 91.6 (36.7) 100 (52.4)  107 (52) 112 (37) 130 (58)  69.8 (29.6) 71.6 (26.3) 70.4 (24.3) 
TS (mm2) 78.0 (20.2) 77.5 (20.1) 80.9 (17.6)  60.2 (5.9) 60.7 (9.3) 64.4 (2.3)  95.9 (9.1) 94.3 (10.7) 97.5 (3.2) 
TbTh (mm) 0.115 (0.010) 0.117 (0.009) 0.118 (10.3)  0.113 (0.011) 0.117 (0.007) 0.121 (0.007)  0.117 (0.009) 0.116 (0.011) 0.115 (0.010) 
TbSp (mm) 0.777 (0.475) 0.697 (0.397) 0.740 (0.382)  0.397(0.110) 0.379 (0.044) 0.398 (0.137)  1.16 (0.37) 1.02 (0.32) 1.08 (0.13) 
TbN (1/mm) 0.555 (0.455) 0.538 (0.315) 0.563 (0.411)  0.876 (0.451) 0.825 (0.119) 0.893 (0.322)  0.234 (0.072) 0.251 (0.064) 0.233 (0.070) 
PoT (%) 93.5 (6.0) 93.7 (3.8) 93.2 (5.2)  89.7 (6.6) 90.3 (1.8) 89.1 (4.3)  97.3 (0.7) 97.1 (0.6) 97.3 (1.0) 
Means (± SD) of samples collected at necropsy. 
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Supplemental Table 5. Biomechanical data of rats in the control and Si-supplemented groups 
 Combined (Males & Females)   Female rats    Male rats  
 
 
Tibia 
Group 1: 
Control 
(n=7) 
Group 2: 
115 mg Si/L 
(n=10) 
Group 3:  
575 mg Si/L 
(n=10) 
 Group 1: 
Control 
(n=5) 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=5) 
 Group 1: 
Control 
(n=2)a 
Group 2: 
115 mg Si/L 
(n=5) 
Group 3: 
575 mg Si/L 
(n=4) 
k (N/mm) 398 (73) 405 (98) 412 (89)  365 (30) 340 (57) 348 (46)  478 470 (89) 491 (55) 
Fy (N) 101 (9.3) 101 (25) 111 (31)  99 (5.3) 89 (18) 87 (6.8)  107 114 (27) 143 (14) 
Fmax (N)d 125 (25) 126 (24)b   120 (8.6) 113 (13) 114 (8.5)  137 156c  
Means (± SD) of samples collected at necropsy. 
aData collected from three of the bones was unreliable due to vibration of the samples during data collection. The measurement protocol was modified 
for remainder of male rat bones. 
bN=7, cN=2. 
dMajority of bones from the male rats did not break with the maximum load of 180 N, allowed by testing apparatus used.  
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Supplemental Table 6. Pearson correlations for serum osteocalcin and serum 17β-estradiola 
  Combined  Male rats  Female rats 
  r p  r p  r p 
Serum Osteocalcin vs. 
 Serum Si 
 Tibia P 
 Tibia Mg 
 Fy (yield strength) 
 
  
-0.57 
 
 
-0.62 
 
0.004 
 
 
0.003 
  
-0.72 
-0.61 
-0.77 
-0.69 
 
0.008 
0.034 
0.003 
0.042 
  
 
 
-0.62 
 
 
 
0.031 
Serum 17β-estradiol vs. 
 tBMD 
 TV 
 BV/TV 
 TS 
 BS/BV 
 TbSp 
 TbN 
 TbTh 
 PoT 
 Serum osteocalcin 
 Ca:P ratio 
 Tibia P 
 Serum K 
 Tibia Zn 
 Tibia length 
 k (stiffness) 
 Fy (yield strength) 
 Body weight 
 Body weight gain 
  
 
0.68 
-0.77 
0.47 
-0.80 
0.56 
-0.68 
0.54 
 
-0.47 
 
-0.58 
0.47 
-0.52 
0.60 
-0.74 
-0.57 
-0.65 
-0.80 
-0.78 
 
 
0.001 
0.0001 
0.043 
0.0005 
0.013 
0.002 
0.016 
 
0.043 
 
0.010 
0.044 
0.023 
0.007 
0.001 
0.018 
0.005 
0.00004 
0.00008 
  
 
 
 
 
 
 
 
 
 
 
0.71 
 
 
 
 
 
 
-0.88 
 
 
 
 
 
 
 
 
 
 
 
0.033 
 
 
 
 
 
 
0.004 
  
 
 
 
 
 
 
 
 
-0.67 
 
 
 
 
 
 
 
 
 
-0.96 
-0.95 
 
 
 
 
 
 
 
 
 
0.05 
 
 
 
 
 
 
 
 
 
0.00005 
0.00008 
aOnly statistically significant correlations are shown.  
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Supplemental Figure 1. 17β-estradiol concentrations of the fasting serum, collected at 
necropsy, of the female (n=9) and male (n=10) rats after 12 weeks supplementation with Si 
(medium or high dose, or vehicle). Data is shown as box-plots where the horizontal lines 
indicate the 5th, 25th, 50th (i.e. median), 75th and 95th percentiles, the open square shows the 
mean and the crosses the minimum and maximum values. Serum 17β-estradiol concentration 
was on average 1.7 fold higher in the female rats compared to the male rats (p = 0.0002, 
independent sample t-test). 
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Supplemental Figure 2. Body weights of female (a) and male (b) rats over the 90 days of 
intervention with the diluent control, 115 mg Si/L and 575 mg Si/L in their drinking water. 
Data are means ± SD of 5 rats at each time points. 
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  Lattice parametersa 
Samples  a c 
1  9.445 6.886 
6  9.449 6.888 
11  9.448 6.884 
a±0.002 
 
Supplemental Figure 3. X-ray diffraction (XRD) analysis of the mineral phase of the tibias 
of female rats after 12 weeks intervention with diluent control (sample 1), 115 mg Si/L 
(sample 6) and 575 mg Si/L (sample 11) in their drinking water. The lattice parameters of the 
three samples are tabulated. 
